laptop_graphics+leaves
Oasis Team

Oasis Team

Cannabis and Hemp Research Firm Oasis Intelligence Names Hilary Craven, Dr. Stuart Silverman to Board

Marketing and Medical Veterans Add Depth and Guidance As Oasis Brings Consumer Insights to the Industry

Having officially launched on January 8, 2020, to offer brand marketers, investors, and multi-state operators in the cannabis and hemp industry badly needed consumer insights, Oasis Intelligence has today announced official appointments to its Board of Advisors, including President and Founder of Sidecar, Hilary Craven and Stuart Silverman, M.D. 

The Oasis Cannabis and Hemp Industry Tracker is the largest proprietary survey of consumer attitudes, perceptions and usage in the cannabis and hemp industry. Its consumer insights are drawn from a 20,000-person, quantitative, state-by-state national study across all demographics. And now Oasis Intelligence will benefit from two experts from the brand marketing and medical cannabis fields. 

“We’re thrilled to have these two experts in their respective fields on our Board of Advisors; putting Oasis at an immediate advantage. We can better understand the patient journey through Dr. Silverman’s experience and expertise and with Hilary Craven on our side we can better serve the c-suite executives and investors in need of leveraging data for successful growth.”

About Hilary Craven

With nearly 20 years experience, Hilary Craven is Founder and Chief Marketing Officer of the marketing company Sidecar, coming from high profile advertising shops including 72andSunny. There she developed and implemented brand and communication strategies for blue chip companies including Sonos, Tillamook, Activision, Samsung, Nike, and Target. Since launching Sidecar, the company has consulted for influential, innovative cannabis brands including dosist. 

Her entrepreneurial and leadership experience has allowed her to now act as an advisor for c- level executives and venture capitalists looking for support in brand identity, articulation and global communication strategy. She is energized around applying her knowledge to this evolving category and continuing to create work that resonates in culture in relevant ways.

About Dr. Stuart Silverman

Stuart Silverman, M.D. is a rheumatology physician, cannabis clinician and researcher in private practice who is a clinical Professor at both Cedars Sinai Medical Center and the David Geffen School of Medicine at UCLA. He is a faculty member of the UCLA Cannabis Research Initiative. He has spoken on the topic of cannabis at venues ranging nationally from Princeton University to locally at TEC-Leimert and giving Grand Rounds on cannabis at both Cedars Sinai and UCLA. He is the author of over 200 peer reviewed original papers. He has served as director of the Cedars Sinai outpatient Fibromyalgia Rehab program and Acting Chief of Rheumatology at West Los Angeles VA Medical Center.

He has served on the Scientific Advisory Board of Kalytera Pharma, which is developing CBD and cannabinoids for treatment of disease, and has worked with Niamedic, an Israeli healthcare and research company specialized in integrating medical cannabis treatments. 

He is part of a diversity initiative at UCRI and has started qualitative research on the cannabis journey in different racial/ethnic groups as well as working with UCRI on educational initiatives.  He has received the Health Network Service Excellence award for his clinical research and practice which include chronic pain, fibromyalgia and osteoporosis. 

He is a graduate of Princeton University, Johns Hopkins medical school and completed his medical training in internal medicine at Boston University. He is board certified in internal medicine, rheumatology and immunology. In his rheumatology practice he helps patients with rheumatologic conditions with chronic pain. He helps patients decrease opioid dependence with use of cannabis and both pharmacologic and non-pharmacologic management.

Stuart Silverman, M.D. is a rheumatology physician, cannabis clinician and researcher in private practice who is a clinical Professor at both Cedars Sinai Medical Center and the David Geffen School of Medicine at UCLA. He is a faculty member of the UCLA Cannabis Research Initiative. He has spoken on the topic of cannabis at venues ranging nationally from Princeton University to locally at TEC-Leimert and giving Grand Rounds on cannabis at both Cedars Sinai and UCLA.

He has served on the Scientific Advisory Board of Kalytera Pharma, which is developing CBD and cannabinoids for treatment of disease, and has worked with Niamedic, an Israeli healthcare and research company specialized in integrating medical cannabis treatments.

The author of over 200 peer reviewed original papers, he is a graduate of Princeton University, Johns Hopkins medical school and completed his medical training in internal medicine at Boston University. 

About Oasis Intelligence

Headquartered in Los Angeles, CA., Oasis Intelligence is a global cannabis and hemp consumer data and insights company that places an emphasis on the voice of the consumer in an industry too narrowly focused on point-of-sale numbers. Our groundbreaking Oasis Cannabis and Hemp Tracking Study™ is the largest state-by-state proprietary survey of consumer attitudes across North America. This unique, human-centric approach is backed by our peerless expertise in quantitative and qualitative consumer market research, brand strategy, and growth strategy. We paint a complete picture of the cannabis and hemp users of today – and the ones of tomorrow.

To find out how we can help your business grow, contact us now. 

Share this post

Share on linkedin
Share on email

how can we help grow your business ?

All rights reserved, Oasis Intelligence, LLC.